These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 22348407)

  • 41. Thrombelastographic monitoring of recombinant factor VIIa in acquired haemophilia.
    Dehmel H; Werwitzke S; Trummer A; Ganser A; Tiede A
    Haemophilia; 2008 Jul; 14(4):736-42. PubMed ID: 18445011
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Replacement therapy for bleeding episodes in factor VII deficiency. A prospective evaluation.
    Mariani G; Napolitano M; Dolce A; Pérez Garrido R; Batorova A; Karimi M; Platokouki H; Auerswald G; Bertrand AM; Di Minno G; Schved JF; Bjerre J; Ingerslev J; Sørensen B; Ruiz-Saez A; ;
    Thromb Haemost; 2013 Feb; 109(2):238-47. PubMed ID: 23238632
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of recombinant activated factor VII vs. activated prothrombin complex concentrate for patients suffering from haemophilia complicated with inhibitors: a Bayesian meta-regression.
    Treur MJ; McCracken F; Heeg B; Joshi AV; Botteman MF; De Charro F; Van Hout B
    Haemophilia; 2009 Mar; 15(2):420-36. PubMed ID: 19335751
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Treatment and prevention of haemorrhage with recombinant activated factor VII, not only in hemophilia].
    Levi M; Friederich PW; van der Meer J
    Ned Tijdschr Geneeskd; 2002 Dec; 146(52):2534-7. PubMed ID: 12532665
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use programme in patients with severe haemophilia or with acquired inhibitors.
    Arkin S; Blei F; Fetten J; Foulke R; Gilchrist GS; Heisel MA; Key N; Kisker CT; Kitchen C; Shafer FE; Shah PC; Strickland D
    Blood Coagul Fibrinolysis; 2000 Apr; 11(3):255-9. PubMed ID: 10870806
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: haemophilia registry data from the Czech Republic.
    Salaj P; Penka M; Smejkal P; Geierova V; Ovesná P; Brabec P; Cetkovsky P; Kubes R; Mesterton J; Lindgren P
    Thromb Res; 2012 May; 129(5):e233-7. PubMed ID: 22386136
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A comparison of traditional vs. Canadian tailored prophylaxis dosing of prophylactic factor infusions in children with haemophilia A and B in a single hemophilia treatment center.
    Dodd C; Watts RG
    Haemophilia; 2012 Jul; 18(4):561-7. PubMed ID: 22221939
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder.
    Yilmaz D; Karapinar B; Balkan C; Akisü M; Kavakli K
    Pediatr Hematol Oncol; 2008 Jun; 25(4):301-11. PubMed ID: 18484474
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bleeding and surgery in children with Glanzmann thrombasthenia with and without the use of recombinant factor VII a.
    Hennewig U; Laws HJ; Eisert S; Göbel U
    Klin Padiatr; 2005; 217(6):365-70. PubMed ID: 16307424
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The burden of bleeds and other clinical determinants on caregivers of children with haemophilia (the BBC Study).
    Khair K; Klukowska A; Myrin Westesson L; Kavakli K; Escuriola C; Uitslager N; Santoro C; Holland M; von Mackensen S
    Haemophilia; 2019 May; 25(3):416-423. PubMed ID: 30925018
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors.
    Martinowitz U; Livnat T; Zivelin A; Kenet G
    Haemophilia; 2009 Jul; 15(4):904-10. PubMed ID: 19473416
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of acute bleeding on daily activities of patients with congenital hemophilia with inhibitors and their caregivers and families: observations from the Dosing Observational Study in Hemophilia (DOSE).
    Recht M; Neufeld EJ; Sharma VR; Solem CT; Pickard AS; Gut RZ; Cooper DL
    Value Health; 2014 Sep; 17(6):744-8. PubMed ID: 25236999
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A cost evaluation of treatment alternatives for mild-to-moderate bleeding episodes in patients with haemophilia and inhibitors in Brazil.
    Ozelo MC; Villaça PR; De Almeida JO; Bueno TM; De Miranda PA; Hart WM; Karamalis M
    Haemophilia; 2007 Sep; 13(5):462-9. PubMed ID: 17880430
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics/pharmacodynamics.
    Shirahata A; Fukutake K; Takamatsu J; Shima M; Hanabusa H; Mugishima H; Amano K; Takedani H; Tamashima S; Matsushita T; Tawa A; Tanaka I; Higasa S; Kosaka Y; Fujii T; Sakai M; Migita M; Kawakami K; Ohashi Y; Saito H
    Haemophilia; 2013 Nov; 19(6):853-60. PubMed ID: 23738888
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparing bleed frequency and factor concentrate use between haemophilia A and B patients.
    Nagel K; Walker I; Decker K; Chan AK; Pai MK
    Haemophilia; 2011 Nov; 17(6):872-4. PubMed ID: 21342368
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment-related knowledge and skills of patients with haemophilia and their informal caregivers.
    Novais T; Duclos A; Varin R; Lopez I; Chamouard V
    Int J Clin Pharm; 2016 Feb; 38(1):61-9. PubMed ID: 26474860
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Factor VIIa and its potential therapeutic use in bleeding-associated pathologies.
    Hedner U
    Thromb Haemost; 2008 Oct; 100(4):557-62. PubMed ID: 18841276
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prevention of arthropathy in haemophilia - intensive on-demand treatment, UK perspective.
    Lee CA
    Haemophilia; 2008 Nov; 14 Suppl 6():11-5. PubMed ID: 19134027
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Experience of recombinant activated factor VII usage during surgery in patients with haemophilia with inhibitors.
    Polyanskaya T; Zorenko V; Karpov E; Sampiev M; Mishin G; Vasiliev D
    Haemophilia; 2012 Nov; 18(6):997-1002. PubMed ID: 22672066
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors.
    Astermark J; Rocino A; Von Depka M; Van Den Berg HM; Gringeri A; Mantovani LG; Morado M; Garrido RP; Schiavoni M; Villar A; Windyga J;
    Haemophilia; 2007 Jan; 13(1):38-45. PubMed ID: 17212723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.